Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics CRSP, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CRSP usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 26 extraordinary options activities for CRISPR Therapeutics. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 46% leaning bullish and 53% bearish. Among these notable options, 3 are puts, totaling $117,440, and 23 are calls, amounting to $1,343,639.
What's The Price Target?
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $45.0 and $110.0 for CRISPR Therapeutics, spanning the last three months.
Volume & Open Interest Trends
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for CRISPR Therapeutics's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of CRISPR Therapeutics's whale activity within a strike price range from $45.0 to $110.0 in the last 30 days.
CRISPR Therapeutics Option Activity Analysis: Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| CRSP | CALL | SWEEP | BULLISH | 09/20/24 | $110.00 | $275.0K | 232 | 503 |
| CRSP | CALL | TRADE | BEARISH | 02/23/24 | $75.00 | $110.2K | 1.2K | 75 |
| CRSP | CALL | TRADE | NEUTRAL | 01/17/25 | $80.00 | $73.0K | 1.9K | 77 |
| CRSP | CALL | TRADE | BEARISH | 03/01/24 | $68.00 | $67.6K | 910 | 153 |
| CRSP | CALL | SWEEP | BULLISH | 02/23/24 | $75.00 | $67.2K | 1.2K | 413 |
About CRISPR Therapeutics
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
In light of the recent options history for CRISPR Therapeutics, it's now appropriate to focus on the company itself. We aim to explore its current performance.
CRISPR Therapeutics's Current Market Status
- With a trading volume of 2,282,563, the price of CRSP is up by 2.43%, reaching $74.55.
- Current RSI values indicate that the stock is may be overbought.
- Next earnings report is scheduled for 13 days from now.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for CRISPR Therapeutics, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
